|
|
|
Molecular Markers, Part 5: Dr. David Spigel on Integrating Markers into Clinical Trials
Here’s part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity. In this podcast, my friend Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN presents on the benefits as well as the challenges of new models of clinical trials in lung cancer that move away from “all comers” to smaller, more limited populations defined by molecular markers. Following his presentation, we continued our panel discussion, covering how much the transition into molecular oncology has disrupted how we do clinical research, as well as how our growing experience with molecular testing is leading us to question some of our previously held beliefs.
Below are the audio and video versions of this podcast, along with the transcript and figures for it.
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Audio Podcast
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Transcript
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Figs
Podcast: Play in new window | Download (Duration: 24:30 — 57.3MB) | Embed
Webinar on Pulmonary Complications in Lung Cancer, with Pulmonologist Gerard Silvestri
Our next webinar will be with Dr. Gerard Silvestri, Professor of Pulmonology and Critical Care Medicine at Medical University of South Carolina in Charleston. Dr. Silvestri is amazingly dynamic and gave one of my favorite talks that was turned into a podcast, on the workup of lung cancer. He’s terrific with patients and can cover difficult concepts very accessibly, really connecting with his audience.
GRACE and LUNGevity Foundation will be partnering to feature him in an upcoming webinar on Wednesday, May 30th, at 7 PM Eastern, 4 PM Pacific, where he will cover topics of pulmonary complications like pleural effusions, obstructed airways and collapsed lung lobes, and coughing up blood, and of course how these can be managed.
Ongoing Great Panel Discussion from the Santa Monica Molecular Markers Webinar: Part 4
Here’s the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss. We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.
Below you’ll find the audio and video versions of the podcast, along with the transcript (no real figures to go with this one).
Molecular Markers SM Pt 4 Panel Discussion Audio Podcast
Molecular Markers SM Pt 4 Panel Discussion Transcript
We’ll continue with a presentation by Dr. Spigel on the value and challenges of incorporating molecular markers into the design of clinical trials in lung cancer.
Podcast: Play in new window | Download (Duration: 16:57 — 32.1MB) | Embed
Molecular Markers Webinar Part 3: Panel Discussion Debating Who to Test and What to Test For:
Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins, Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa and NCI-Canada’s Lung Cancer Committee.
In this continuing portion of the program, we have a debate on the merits of uniform vs. more selective testing of “druggable” mutations and consider whether it is more attractive to test for multiple markers simultaneous or perhaps sequentially, since they are typically mutually exclusive. We also discuss the challenge of the delays in treatment that may become a real clinical problem for some patients if testing may require a few weeks of downtime.
Below you’ll find the audio and video versions of the podcast, along with the transcript and figures for this activity.
Molecular Markers SM Pt 3 Panel Discussion Audio Podcast
Molecular Markers SM Pt 3 Panel Discussion Transcript
Molecular Markers SM Pt 3 Panel Discussion Figs
Podcast: Play in new window | Download (Duration: 17:28 — 38.3MB) | Embed
Dr. Alice Shaw on Clinical Factors Associated with Molecular Markers
I’m happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on “Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?“, in which I was joined by Drs. Charles Rudin (Johns Hopkins University in Balimore, MD), Alice Shaw (Massachusetts General Hospital in Boston, MA), David Spigel (Sarah Cannon Cancer Center in Nashville, TN), and Glen Gloss (University of Ottawa in Ontario, Canada).
In this short podcast, Dr. Alice Shaw reviewed the frequencies of different molecular markers in advanced NSCLC as a function of patient sex, smoking status, race, and tumor histology. This work is very interesting, of course, because if we only do molecular marker studies of people with an adenocarcinoma or never-smokers, we not only won’t ever find potentially relevant mutations in people with other histologies and those with a smoking history, but we won’t have any good idea of the probabilities of finding them either.
Here is the podcast in audio and video formats, as well as the transcript and figures.
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Audio Podcast
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Transcript
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Figs
Podcast: Play in new window | Download (Duration: 10:48 — 24.9MB) | Embed
Molecular Markers in Lung Cancer: Dr. Charlie Rudin on the Lung Cancer Mutation Consortium
This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica “Targeted Therapies in Lung Cancer” meeting several weeks ago. There, I was privileged to be joined by four excellent guest faculty members — Dr. Charles Rudin from Johns Hopkins University in Baltimore, Dr. Alice Shaw from Massachusetts General Hospital in Boston, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, and Dr. Glen Goss from the University of Ottawa. They each brought their rich experience and some differing perspectives on the complex and evolving topic of how to apply new work on molecular markers in lung cancer to clinical practice.
Below you’ll find links to the audio and video versions of the podcast, along with the transcript and figures.
Molecular Markers SM Pt 1 Rudin on LCMC Audio Podcast
Molecular Markers SM Pt 1 Rudin on LCMC Transcript
Molecular Markers SM Pt 1 Rudin on LCMC Figures
Podcast: Play in new window | Download (Duration: 17:36 — 40.6MB) | Embed
Question and Answer Session with Dr. Weiss on Lung Cancer Highlights, 2011
Here’s the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 — the question and answer session that followed his presentation. Below is the transcript, figures, and the audio and video versions of the podcast.
Dr. Weiss Lung Cancer Highlights 2011 Q and A Transcript
Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Figs
Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Audio Podcast
Podcast: Play in new window | Download (Duration: 18:14 — 40.0MB) | Embed
Dr. Weiss’s “Highlights in Lung Cancer, 2011″: CT Screening & Optimal Management of Elderly Patients with Advanced NSCLC
This is the third and final part of Dr. Weiss’s presentation on “Highlights in Lung Cancer, 2011″. After focusing on developments in relatively narrow subpopulations with distinct molecular markers in the first two parts of his webinar, Dr. Weiss closed with his coverage of a couple of issues with broader applicability: the new data supporting CT screening for higher risk people with a significant smoking history, and also some new data addressing the question of whether elderly patients are best served by receiving single agent or doublet chemotherapy.
Below you’ll find the podcast of the program in audio and video formats, as well as the transcript and figures for this activity.
Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Audio Podcast
Dr. Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Transcript
Dr Weiss Highlights in Lung Cancer 2011, Pt. 3 CT Screening and LC in Elderly Figs
Podcast: Play in new window | Download (Duration: 13:57 — 40.8MB) | Embed
2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis
Apologies for the long wait since our own Dr. Weiss’s upbeat and thoughtful review of the leading stories about lung cancer in 2011. Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we’ve broken that up into several short pieces that cover a few highlights at a time. In fact, we’re going to make an effort to have podcasts shorter and easier to digest in the future.
The first part is on EGFR-based therapies, including the EURTAC trial of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) vs. standard doublet chemo in a European, EGFR mutation-positive patient population, followed by work on EGFR TKI/monoclonal antibody combinations: one being the single arm afatinib/Erbitux (cetuximab) for patients with acquired resistance after a good response to earlier EGFR TKI therapy, and the second being Tarceva with either the c-MET antibody MET-MAb or placebo.
Here’s the audio and video versions of the podcast, along with the transcript and figures for this portion of the program.
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Audio Podcast
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Transcript
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Figs
Podcast: Play in new window | Download (Duration: 11:13 — 39.1MB) | Embed
Tips and Tools on Smoking Cessation, by Dr. Mark Millard
This long-overdue podcast by Dr. Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University in Dallas, TX, focuses on many aspects of smoking cessation: how physicians can effectively discuss it with patients, how anyone can discuss the issue constructively with a smoker, and how someone motivated to quit can use a wide range of tools — both behavioral and medical — to optimize their chance of quitting for good.
Here are the audio and video versions of the podcast, along with the transcript and figures for the program.
Dr. Millard Tips and Tools for Smoking Cessation Audio Podcast
Dr. Millard Tips and Tools for Smoking Cessation Transcript
Dr. Millard Tips and Tools for Smoking Cessation Figures
Podcast: Play in new window | Download (Duration: 27:50 — 69.3MB) | Embed
| Follow us on... |    |
||
Copyright ©2012 GRACE |
|||